Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $73

Benzinga Newsdesk www.benzinga.com Positive 70.6%

Neg 0% Neu 0% Pos 70.6%

Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $48 to $73.